Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features

Deborah A. Bowen, Timothy G. Call, Greg D. Jenkins, Clive Z. Zent, Susan M. Schwager, Daniel L. Van Dyke, Diane F. Jelinek, Neil E. Kay, Tait D. Shanafelt

Research output: Contribution to journal › Article › peer-review

88 Scopus citations

Fingerprint

Dive into the research topics of 'Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features'. Together they form a unique fingerprint.

Medicine & Life Sciences